Shenzhen Salubris Pharmaceuticals Announces RMB 310 Million Cash and Subsidiary Equity Investment to Expand Biomedical Subsidiary

Salubris (002294.SZ) announced that, in accordance with the company’s development plan, it intends to increase the capital of its wholly-owned subsidiary, Shenzhen Salubris Biomedical Engineering Co., Ltd. (“Salubris Medtech”), by contributing RMB 310 million in cash, its 100% equity interest in Suzhou Huanchen Medical Technology Co., Ltd. (“Suzhou Huanchen,” corresponding to a registered capital of RMB 22.826088 million) valued at RMB 189.040618 million, and its 63.37% equity interest in In Biological Science And Technology (Beijing) Co., Ltd. (“In Bio,” corresponding to a registered capital of RMB 4.020521 million) valued at RMB 139.067465 million. Upon completion of the capital increase, the registered capital of Salubris Medtech will rise from RMB 112.244898 million to RMB 750.352981 million, and Salubris Medtech will become the controlling shareholder of Suzhou Huanchen and In Bio, holding 100% of the equity in Suzhou Huanchen and 63.37% of the equity in In Bio.